Stay updated with breaking news from Erytech Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NANTES, France--(BUSINESS WIRE)--Regulatory News:Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced today that the Lyon Commercial Court has rejected Akkadian's request to postpone the vote on...
Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced today
In February, Erytech Pharma SA (NASDAQ: ERYP) announced its proposed combination with Pherecydes Pharma S.A. In June, Erytech announced that Akkadian initiated proceedings to postpone the vote, scheduled on 23 June, on the merger with Pherecydes. The merger would see Pherecydes absorbed into publicly listed Erytech, with Pherecydes shareholders receiving 15 new Erytech shares for every four of their current shares. Monday, Erytech Pharma responded to what it described as Akkadian Partners' "disi
In February, Erytech Pharma SA (NASDAQ: ERYP) announced its proposed combi
The study should include 12 patients, and its launch is expected in the third quarter of 2023NANTES, France--(BUSINESS WIRE)--Regulatory News:Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today ann...